广州丙肝治疗医院丙肝治疗.pptVIP

* Slide 30. Consistent improvement with 72 weeks’ therapy in G1 patients with a partial EVR Conversely, 72 weeks’ treatment of genotype 1 patients with a pEVR (defined as no RVR and 2 log10 drop but HCV RNA 50 IU/mL at week 12) consistently improved SVR rates compared with those observed with the standard duration of 48 weeks. Sánchez-Tapias JM, et al. APASL 2007; Abstract 0-196 * Slide *. Optimising outcomes in genotype 1/4 * * * * * Slide 48: Benefit from intensification of treatment in G2/3 patients without an RVR In a retrospective analysis from a randomised, multicentre phase III studies in which patients were treated with PEGASYS? 180 ?g/wk plus COPEGUS? 800 or 1000/1200 mg/day, Willems et al. looked at whether an intensified regimen may be beneficial in HCV genotype 2/3 patients who do not achieve an RVR.1,2 Patients who did not achieve an RVR demonstrated disappointing SVR rates with the recommended 24 weeks of treatment. However, higher SVR rates and lower relapse rates were observed in patients receiving more intense treatment with a longer treatment duration and higher ribavirin dose.2 Hadziyannis S, et al. Ann Intern Med 2004; 140: 346 Willems B, et al. 42nd EASL 2007; Abstract 8 * Slide *. Optimising outcomes in genotype 1/4 * * * * Slide *. Will a high induction dose improve SVR? Spanish high-dose induction pilot trial The objective of this study was to determine whether treatment with induction doses of PEGASYS? combined with COPEGUS? for the first 12 weeks of a 48-week regimen improves SVR rates in patients infected with HCV genotype 1, who did not respond to previous combination therapy with conventional interferon alfa plus ribavirin. Induction doses of PEGASYS? used in the trial were 180 μg/week, 270 μg/week and 360 μg/week. Diago M, et al. 55th AASLD 2004; Abstract 522 * * * 西班牙研究：增加派罗欣剂量可提高SVR 对普通干扰素+利巴韦林治疗无应答的患者，增加派罗欣剂量可以提高SVR率 *EVR：在第12周时， HCV RNA 50 IU/mL ** SVR：疗程结束后24周，HCV RNA 50 IU/mL 38% 30% 18% SVR** 派罗欣?180?g/周+ 利巴韦林(n=28) 派